<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41539">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02565615</url>
  </required_header>
  <id_info>
    <org_study_id>A2581197</org_study_id>
    <nct_id>NCT02565615</nct_id>
  </id_info>
  <brief_title>Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World Setting</brief_title>
  <acronym>ATTENTION</acronym>
  <official_title>Atorvastatin Effectiveness And Safety In Cardiology Patients In Real World Setting: A Registry Study In China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to verify atorvastatin effectiveness and safety in Chinese population, and
      explore the optimal atorvastatin regimens in high-to-moderate risk for ASCVD。
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2016</start_date>
  <completion_date type="Anticipated">March 7, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 7, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Weeks</target_duration>
  <primary_outcome>
    <measure>The proportion of patients who achieve LDL-C goal value at 12-week atorvastatin therapy according to Chinese Guideline on Dyslipidemia Prevention and Treatment in Adult (2007 version).</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dosage distribution of atorvastatin in patients within different risk categories as defined by Chinese Guideline on Dyslipidemia Prevention and Treatment in Adult (2007) at the end of 12-weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients who dropout and reason</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Dropouts percentage and reason through 12 weeks of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who present with muscle related adverse event</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Muscle related adverse event includes symptoms such as myalgia, fatigue, weakness, creatine kinase values 10 times the upper limit of normal, and rhabdomyolysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who present with persistent elevation of liver enzyme</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Persistent elevations in Alanine Aminotransferase/ Aspartate Aminotransferase (ALT/AST) ＞3 Upper Limit of Normal (ULN)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who present with major adverse cardiovascular events</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>MACE includes death from all-cause or cardiac death, myocardial infarction, documented unstable angina requiring re-hospitalization, revascularization with either percutaneous coronary intervention or coronary-artery bypass grafting, stroke</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Coronary Artery Disease, Hypercholesterolemia, Hypertension</condition>
  <arm_group>
    <arm_group_label>Atorvastatin dose titration (single-arm)</arm_group_label>
    <description>Judged by investigators, patients in cardiology department who are using atorvastatin can be included into this study, if they are eligible. During the study, the dose can be titrated based on the judgement of investigator</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>Because this is a non-interventional study, there is no intervention here.</description>
    <arm_group_label>Atorvastatin dose titration (single-arm)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese cardiology patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged ≥18 years;

          -  Cardiology patients who has been prescribed atorvastatin by physician's clinical
             judgment under normal clinical care. These patients will include those with
             established coronary heart disease, or having multiple risk factors and at risk for
             cardiovascular disease, or primary hypercholesterolemia.

          -  Baseline laboratory reports prior to starting atorvastatin therapy can be tracked ,
             including lipid measurement, liver function, and Creatine Kinase (CK) value. The date
             of baseline reports should be within 1 month before taking atorvastatin.

          -  Evidence of a personally or his/her legally acceptable representative signed and
             dated informed consent document indicating that the patient has been informed of all
             pertinent aspects of the study and accept follow-up visit.

        Exclusion Criteria:

          -  Patients who have regularly taken atorvastatin therapy more than 4 weeks before
             enrollment

          -  Concomitant any other lipid-lower medication at baseline, or during the study
             conduction on physician clinical judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>First People's Hospital of Fuyang City</name>
      <address>
        <city>Fuyang</city>
        <state>Anhui</state>
        <zip>236000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Meitan General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100028</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fu Xing Hospital Affiliated to Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NAVY General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100048</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guang'anmen hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Meitan General Hospital</name>
      <address>
        <city>Biejing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chongqing Dianjiang People's Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yongchuan hospital of chongqing medical university</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>402160</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chongqing Wanzhou People's Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>404100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fuling center hospital of chongqing city</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>408000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xiamen Cardiovascular Hospital</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangdong Pharmaceutical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510580</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jiangmen Central Hospital</name>
      <address>
        <city>Jiangmen</city>
        <state>Guangdong</state>
        <zip>529000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of henan university of TCM</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The central hospital of Shangluo city</name>
      <address>
        <city>Shangluo</city>
        <state>Shaanxi</state>
        <zip>726000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ji'nan Central Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quzhou Hospital of Zhejiang University</name>
      <address>
        <city>Quzhou</city>
        <state>Zhejiang</state>
        <zip>324000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital attached to aeromedicine institute of P.L.A (466 Hospital)</name>
      <address>
        <city>Beijing</city>
        <zip>100089</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The first people's Hospital of Xiaoshan District</name>
      <address>
        <city>Hangzhou</city>
        <zip>311200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nanjing Red Cross Hospital</name>
      <address>
        <city>Nanjing</city>
        <zip>210001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cardiology Provincial Hospital of Jiangsu Province</name>
      <address>
        <city>Nanjing</city>
        <zip>210024</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jiangning People's Hospital</name>
      <address>
        <city>Nanjing</city>
        <zip>211100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nanjing colleague hospital</name>
      <address>
        <city>Nanjing</city>
        <zip>211102</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shanghai University of Traditional Chinese Medicine affiliated Yueyang Hospital of traditional Chine</name>
      <address>
        <city>Shanghai</city>
        <zip>200082</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shanghai Minhang District Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>201111</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lanxi Municipal People's Hospital</name>
      <address>
        <city>Zhejiang</city>
        <zip>321100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A2581197&amp;StudyName=Atorvastatin%20Effectiveness%20And%20Safety%20In%20Cardiology%20Outpatients%20In%20Real%20World%20Setting%3A%20A%20Registry%20Study%20In%20China</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A2581197&amp;StudyName=Atorvastatin+Effectiveness+And+Safety+In+Cardiology+Patients+In+Real+World+Setting%3A+A+Registry+Study+In+China</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 21, 2017</lastchanged_date>
  <firstreceived_date>September 15, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
